Acute lobar nephronia, is also termed as acute focal pyelonephritis or acute focal bacterial pyelonephritis. It is a non-liquefactive focal severe infection involving one or more renal lobules. It is a type of medical renal disease that presents as a febrile urinary tract infection. The typical symptoms include fever, leukocytosis, pyuria, flank pain, and bacteriuria, which are similar to those with renal abscess.

Acute lobar nephronia is normally witnessed in children. This condition is being increasingly diagnosed due to the advancement of imaging technology. The rise in paediatric population, growing cases of bacterial infection, and increased innovations in the disease treatment field will boost the market growth. Around 25% of the children with this condition may progress into renal abscess if not treated with suitable and adequate intravenous antibiotics

Data Bridge Market Research analyses that the acute lobar nephronia treatment market is expected to reach USD 11.72 billion by 2030, which is USD 8.9 billion in 2022, and is expected to undergo a CAGR of 3.50% during the forecast period 2023 to 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Access Report Summary @ https://www.databridgemarketresearch.com/reports/global-acute-lobar-nephronia-treatment-market

North America is dominating the market in the forecast period because of the strong reimbursement policies in the U.S. and increasing awareness and research towards this disease. Asia-Pacific is considered to have the most lucrative period because of the increasing research and development investments and rising expenditure on healthcare.

Key players operating in the acute lobar nephronia treatment market include:

Hikma Pharmaceuticals PLC (U.K.)
Pfizer Inc. (U.S.)
Bristol-Myers Squibb Company (U.S.)
Antares Pharma (U.S.)
Novartis AG (Switzerland)
Teva Pharmaceutical Industries Ltd (Israel)
F. Hoffmann-La Roche Ltd (Switzerland)
Fresenius Kabi USA (U.S.)
Accord Healthcare, Inc. (U.S.)
GSK plc (U.K.)
Lilly (U.S.)
Abbott (U.S.)
Sanofi (France)
Bayer AG (Germany)
Amgen Inc. (U.S.)

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com